News

New BIO Report Highlights Virginia’s Bioscience Industry Increases Jobs, NIH Awards and More

The Biotechnology Innovation Organization (BIO) released new data on the bioscience industry in the United States in their report, The Bioscience Economy: Propelling Life-Saving Treatments, Supporting State & Local Communities. This report outlines the bioscience industry’s economic footprint across the nation and in Virginia, as well as the significant role played by small- and mid-sized companies. The report further analyzes the industry’s response to the COVID-19 pandemic, and more broadly highlights the importance of the bio-ecosystem in times of pandemic, which requires rapid response and innovation.

The report recognizes Virginia at the national level for steady growth of NIH research funding and specialized employment in the bioscience, agricultural feedstock, and pharmaceutical subsectors. At the Commonwealth level, the bioscience industry outperformed the private sector with increases in wages and establishments. Virginia also experienced steady increases across the board in the bioscience industry as shown below.

● $86,212 average annual wage
● 24,346 employees
● 2,058 establishments
● $854M bioscience-related R&D expenditures
● $506.1M total NIH funding

”The bioscience industry plays a critical role in Virginia of creating jobs, quality wages, and innovative technologies. Virginia Bio is proud to serve as an advocate to our members whose businesses and technologies feed this bio-ecosystem. Members, who are in our own backyards, are working on life-saving technologies and reaching national recognition for their accolades. This bio-ecosystem must be protected to ensure vitality of this industry and to maintain its role as an economic driver in Virginia,” said John Newby, CEO of Virginia Biotechnology Association.

The state-by-state industry assessment is the ninth in a biennial series, developed in partnership by TEConomy and BIO, and studies the state of the U.S. bioscience industry and its associated innovation ecosystem at the national, state, and metropolitan area levels.

The analysis includes a fact sheet for Virginia, which can be found via the interactive map at www.bio.org/jobs.

Recent News

09/03/2026

Seppic announces the appointment of Virginie Cavalli as Chief Executive Officer

A subsidiary of Air Liquide Healthcare, Seppic designs, manufactures, and distributes a wide range of specialty ingredients used in cosmetics, nutraceuticals, pharmaceuticals, veterinary products, and industrial applications. Nearly 900 employees support customers in 100 countries through the company’s subsidiaries and distributor network. With a degree from EMLyon school in business and financial strategy, Virginie Cavalli

09/01/2026

Andre Marshall to join National Science Foundation; Aurali Dade named Interim Vice President for Research, Innovation, and Economic Impact

Since joining George Mason in 2021, Marshall has played a pivotal role in advancing the university’s research enterprise and entrepreneurial ecosystem and strengthening the university’s reputation as a leading public R1 institution, including launching the Grand Challenge Initiative and empowering institute-driven initiatives like Nexus234 and the Virginia Climate Center. During Marshall’s tenure, George Mason expanded research activity and strategic partnerships,

08/25/2026

United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the FDA has accepted the New Drug Application (NDA) for ralinepag to treat PAH. The FDA has set a Prescription Drug User Fee Act target action date of June 24, 2027. Ralinepag has not been approved for use in any indication by the